Use of prostaglandin E1, E2 or analogs to prevent renal failure

Details Use of prostaglandin E1, E2 or analogs to prevent renal failure Use of prostaglandin E1, E2 or analogs to prevent renal failure

1995-11-28

1998-09-15

Ivy, C. Warren

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

A61K 31557

Patent

active

058078959

ABSTRACT:
A method of preventing renal failure or dysfunction caused by medical tests which utilize contrast media by administering, preferably by intravenous infusion or injection, a prostaglandin selected from PGE.sub.1, PGE.sub.2, PGI.sub.2 or an analog or pharmaceutically acceptable salt thereof and preferably in a form of a complex with .alpha.-cyclodextrin, to a patient at risk, for example, a diabetic.

REFERENCES:
patent: 3636120 (1972-01-01), Pike
patent: 3828106 (1974-08-01), Rudel
patent: 3833640 (1974-09-01), Pike
patent: 3914282 (1975-10-01), Pike
patent: 3922297 (1975-11-01), Pike
patent: 3969376 (1976-07-01), Magerlein
patent: 3984455 (1976-10-01), Beal, III et al.
patent: 4054736 (1977-10-01), Hayashi et al.
patent: 4097516 (1978-06-01), Buckler
patent: 4103026 (1978-07-01), Carlson
Wiegmann, "Contrast Nephrotoxicity: The Role of Prostaglandins and Effect of Misorprostol Treatment", National Technical Information Service database, 1992.
L. Gurkowski et al., "Prevention of Contrast Induced Renal Dysfunction by Misoprostil: Results of a Prospective, Randomized, Double-Blind Study", Journal of American Society of Nephrology, vol. 5, No. 3, Sep. 1994.
L. Gurkowski et al., "Misoprostil Prevents Reductions in Renal Blood Flow After Radio-Contrast Infusion During Prostaglandin Inhibition with Indomethacin", Journal of American Society of Nephrology, vol. 5, No. 3, Sep. 1994.
Eur. J. Nucl. Med., vol. 14, No. 5-6, 1988, p. 297, XP000569763, Z. Szabo et al., "Investigation of the Renal Protective Effects of Prostaglandine E 1 (PGE1) in Experimental Ischemia: Measurement of Renal Function with Tc . . . ", see abstract.
Eur. J. Vasc. Surg., vol. 3, No. 1, Feb. 1989, pp. 5-13, XP000569756, G. Torsello et al., "Effects of Prostaglandin E1 (PGE1) on Experimental Renal Ischaemia", see abstract.
Fukushima J. Med. Sci., vol. 39, No. 2, Dec. 1993, pp. 117-119, XP000569761, Y. Matsumoto et al., "Systematic Mangement of Graft-Versus-Host Disease (GVHD)" see abstract.
Invest. Radiol., vol. 10, No. 4, 1975, pp. 284-299, XP000569755, P. S. Moskowitz et al., "Diuresis and Improved Renal Hemodynamics Produced by Prostaglandin E1 in the Dog with Norepinephrine-Induced Acute Renal Failure" see p. 298.
Prostaglandins Leukotrienes Med., vol. 9, No. 1, 1982, pp. 85-107, XP000569781, A. K. Mandal et al., "The Spleen and Acute Renal Failure: Mechanisms of Renal Protection by Splenectomy. Involvement of Prostaglandins", see abstract.
Am. J. Cardiol., vol. 66, No. 14, 1990, pp. 18F-22F, XP000569719, G. A. Porter, "Experimental Contrast-Associated Nephropathy and Its Clinical Implications", see abstract.
Invest. Radiol., vol. 23, No. Suppl. 1, Sep. 1988, pp. s178-s181, XP000569760, Z. Parvez et al., "Effect of Contrast Media on Prostaglandin Synthesis In Vivo" see abstract.
Solomon et al., Effects of Saline, Mannitol, and Furosemide on Acute Decreases in Renal Function Induced by Radiocontrast Agents, The New England Journal of Medicine, vol. 331, No. 21, 1416-1420 (1994).
Textbook of Internal Medicine, published by J.B. Lippincott Company, Philadelphia, 2d Edition, vol. 1, p. 817 (1992).
Weisberg et al., Risk of Radiocontrast Nephropathy in Patients With and Without Diabetes Mellitus, Kidney International, vol. 45, 259-265 (1994).
Olivero, Postsurgical Acute Renal Failure: Which Patients are at Greatest Risk?, Journal of Critical Illness, vol. 9, No. 7, 673-685 (Jul. 1994).
Cantley et al., Role of Endothelin and Prostaglandins in Radiocontrast-Induced Renal Artery Constriction, Kidney International, vol. 44, 1217-1223 (1993).
Abe et al., The Effect of Prostaglandin E.sub.1 During Cardiopulmonary Bypass on Renal Function After Cardiac Surgery, Europe Journal of Clinical Pharmacology, vol. 45, 217-220 (1993).
Pollack et al., A Trial of the Prostaglandin E.sub.1 Analogue, Enisoprost, to Reverse Chronic Cyclosporine-Associated Renaly Dysfunction, American Journal of Kidney Diseases, vol. XX, No. 4, 336-341 (1992).
Moran et al., Prevention of Acute Graft Rejection by the Prostaglandin E.sub.1 Analogue Misoprostol in Renal-Transplant Recipients treated with Cyclosporine, The New England Journal of Medicine, vol. 332, No. 17, 1183-1188 (1990).
Broggi et al., Systemic Administration of the PGE-1 Analogue Alprostadil for Prophylaxis of Early Kidney Graft Failure, Transplantation Proceedings, vol. 21, No. 1, 1546-1547 (1989).
Ninomeya et al., Renal Effects of Prostaglandin E.sub.1 Type 2 (Non-Insulin-Dependent) Diabetic Patients with Subclinical Nephropathy, Diabetes Research, vol. 10, 129-134 (1985).
Niwa et al., Beneficial Effects of Prostaglandin E.sub.1 in Rapidly Progressive Clomerulonephritis, The New England Journal of Medicine, vol. 308, No. 16, p. 969 (Apr. 21, 1983).
Niwa et al., Improvement of Renal Function with Prostaglandin E.sub.1 Infusion in Patients with Chronic Renal Disease, The Lancet, p. 687 (Mar. 20, 1982).
Goodman & Gilman's: "The Pharmacological Basis of Therapeutics", Eight Edition, Chapter 24, 600-611 (1990).

Affiliated with

Also associated with

Rating

Use of prostaglandin E1, E2 or analogs to prevent renal failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of prostaglandin E1, E2 or analogs to prevent renal failure , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of prostaglandin E1, E2 or analogs to prevent renal failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-88010